Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in ...
Vir Biotechnology's share price has plummeted 76% over the last three years, with revenue dropping 44% annually. Despite not making a profit, the company's weak fundamental performance is reflected in its swift share price decline at an annual compound rate of 21%. Investors should be cautious, as buying a steeply falling share price is often compared to 'catching a falling knife'.
TD Cowen Sticks to Its Buy Rating for Vir Biotechnology (VIR)
TD Cowen's Phil Nadeau maintains Buy rating on Vir Biotechnology (VIR), with shares closing at $7.49. Nadeau, with a 5.5% average return and 44.49% success rate, covers Biogen, BioMarin, and Annexon. Analyst consensus rates VIR as Moderate Buy with a $36.00 target. Vir reported $3.08M revenue and $138.38M GAAP net loss for Q2, compared to $3.8M revenue and $194.78M loss in the prior year. Vir Biotechnology focuses on treating infectious diseases using antibody, T cell, innate immunity, and siRNA technologies.
Vir Biotechnology Reports Q3 2024 Financial Results
Vir Biotechnology, Inc. reported Q3 2024 earnings with total revenues of $2.4 million and a net loss of $213.7 million. Key developments include a Sanofi licensing agreement, leadership appointments, and updates on hepatitis and oncology pipelines. The company restructured, reducing its workforce and phasing out certain programs, focusing on hepatitis delta and B programs, with oncology data expected in early 2025. Management is optimistic about future milestones.
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Vir Biotechnology's Q3 2024 earnings call featured updates from CEO Marianne De Backer, CMO Mark Eisner, and CFO Jason O'Byrne, discussing forward-looking statements and risks detailed in SEC filings.
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vir Biotechnology reports Q3 2024 financial results, including a net loss of $213.7 million, and provides updates on its pipeline, including the closing of an exclusive worldwide licensing agreement with Sanofi for three clinical-stage T-cell engagers. Key data from Phase 2 SOLSTICE trial in chronic hepatitis delta to be presented at AASLD 2024. Jason O'Byrne appointed as CFO. Conference call scheduled for October 31, 2024.
Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Vir Biotechnology reports Q3 2024 financial results, including a $1.19 billion cash balance, and provides updates on its pipeline, including a licensing agreement with Sanofi for three clinical-stage dual-masked T-cell engagers, with initial data expected in Q1 2025. Key Phase 2 SOLSTICE data on chronic hepatitis delta will be presented at AASLD 2024, followed by a Hepatitis Investor Event on November 19, 2024. Jason O'Byrne is appointed as CFO, and a conference call is scheduled for October 31, 2024.
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
Vir Biotechnology reported a Q3 loss of $1.56 per share, missing estimates by -62.50%, with revenues of $2.38 million, down 72.54% from estimates. The stock has underperformed the market, down 24.5% YTD, while the Zacks Rank #3 suggests it will perform in line with the market.
© Copyright 2024. All Rights Reserved by MedPath